BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
BioXcel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026
- Market cap
- $757.50K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.2850 (−98.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BioXcel Therapeutics, Inc. saw revenue fall 14.5% to $742.00K over the twelve months to Jun 30, 2026. Free cash flow was -$50.90M.
Revenue
$742.00K
-14.5% vs. a year earlier
Operating income
-$44.93M
TTM Q2 2026
Free cash flow
-$50.90M
TTM Q2 2026
EPS, diluted
-$3.78
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $757.50K
- P/E ratio
- –
- Price to sales
- 1.02
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6720.00%
Fundamentals
- Revenue
- $742.00K
- Net income
- -$70.86M
- EPS, diluted
- -$3.78
- Free cash flow
- -$50.90M
- Book value per share
- -$3.81
- Diluted shares
- 30M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$742.00K-14.5% YoY
Gross profit
$394.00K
Operating income
-$44.93M
Net income
-$70.86M
EPS, diluted
-$3.78
Free cash flow
-$50.90M
Reported periodTrailing twelve months